Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology

Jordan E Pinsker, Lars Müller, Alexandra Constantin, Scott Leas, Michelle Manning, Molly McElwee Malloy, Harsimran Singh, Steph Habif, Jordan E Pinsker, Lars Müller, Alexandra Constantin, Scott Leas, Michelle Manning, Molly McElwee Malloy, Harsimran Singh, Steph Habif

Abstract

Background: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. Methods: Individuals with type 1 diabetes (T1D) (≥14 years of age) who had ≥21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). Patient-reported outcomes (PROs) and glycemic outcomes were reviewed at each timepoint. Results: Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect® web application. Time in range was 78.2% (70.2%-85.1%) at T1 and 79.2% (70.3%-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the continuous glucose monitoring system as being valuable features of the system. Conclusions: Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended TIR glycemic outcomes in people with T1D.

Keywords: Artificial pancreas; Automated insulin delivery; Glycemic control; Patient-reported outcomes; Type 1 diabetes.

Conflict of interest statement

J.E.P. reports grant support, provided to his institution, consulting fees, and speaker fees from Tandem Diabetes Care, Inc; grant support, provided to his institution, and advisory board fees from Medtronic; grant support, provided to his institution, and consulting fees from Eli Lilly; grant support and supplies, provided to his institution, from Insulet; and supplies, provided to his institution, from Dexcom, Inc., L.M. reports grant support from Dexcom, Inc., and consulting from Tandem Diabetes Care, Inc., A.C., S.L., M.M., M.M.M., H.S., and S.H. are employees of Tandem Diabetes Care, Inc.,

Figures

FIG. 1.
FIG. 1.
Study recruitment and analysis.

References

    1. Brown SA, Kovatchev BP, Raghinaru D, et al. : Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381:1707–1717
    1. Dadlani V, Pinsker JE, Dassau E, Kudva YC: Advances in closed-loop insulin delivery systems in patients with type 1 diabetes. Curr Diab Rep 2018;18:88.
    1. Pinsker JE, Li Z, Buckingham BA, et al. : Exceptional usability of Tandem t:slim X2 with Basal-IQ predictive low-glucose suspend (PLGS)—The PROLOG Study. Diabetes 2018;67:db18-86-LB.
    1. Barnard K, James J, Kerr D, Adolfsson P, Runion A, Serbedzija G: Impact of chronic sleep disturbance for people living with T1 diabetes. J Diabetes Sci Technol 2016;10:762–767
    1. Barnard KD, Wysocki T, Ully V, et al. . Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. J Diabetes Sci Technol 2017;11:1080–1088
    1. Stone MP, Agrawal P, Chen X, et al. . Retrospective analysis of 3-month real-world glucose data after the MiniMed 670G System Commercial Launch. Diabetes Technol Ther 2018;20:689–692
    1. Pinsker JE, Leas S, Muller L, Habif S. Real world improvements in hypoglycemia in an insulin-dependent cohort pre and post Tandem Basal-IQ Technology remote software update. Endocr Pract 2020;26:714–721
    1. Muller L, Habif S, Leas S, Aronoff-Spencer E: Reducing hypoglycemia in the real world: a retrospective analysis of predictive low-glucose suspend technology in an ambulatory insulin-dependent cohort. Diabetes Technol Ther 2019;21:478–484
    1. Mueller L, Constantin A, Singh H, Habif S: 95-LB: Control-IQ Technology in the real world: the first 30 days. Diabetes 2020;69:95-LB
    1. Habif S, Constantin A, Muelller L, Singh H: 126-LB: Glycemic outcomes for people with type 1 and type 2 diabetes using Control-IQ Technology: real-world data from early adopters. Diabetes 2020;69:126-LB
    1. Weissberg-Benchell J, Hessler D, Polonsky WH, Fisher L: Psychosocial impact of the bionic pancreas during summer camp. J Diabetes Sci Technol 2016;10:840–844
    1. Hajos TR, Pouwer F, Skovlund SE, et al. : Psychometric and screening properties of the WHO-5 well-being index in adult outpatients with Type 1 or Type 2 diabetes mellitus. Diabet Med 2013;30:e63–e69
    1. Manning ML, Singh H, Stoner K, Habif S: The development and psychometric validation of the diabetes impact and device satisfaction scale for individuals with type 1 diabetes. J Diabetes Sci Technol 2020;14:309–317
    1. Battelino T, Danne T, Bergenstal RM, et al. : Clinical Targets For Continuous Glucose Monitoring Data Interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–1603
    1. American Diabetes Association. 6. Glycemic targets: standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S66–S76
    1. Maahs DM, Buckingham BA, Castle JR, et al. : Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care 2016;39:1175–1179
    1. Brown SA, Beck RW, Raghinaru D, et al. : Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Diabetes Care 2020;43:1822–1828
    1. Beck RW, Brown SA, Lum JW, Kovatchev BP: Nonadjunctive use of continuous glucose monitoring: the end of fingersticks? Diabetes Technol Ther 2020;22:67–68
    1. Forlenza GP, Li Z, Buckingham BA, et al. : Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG Trial. Diabetes Care 2018;41:2155–2161
    1. Foster NC, Beck RW, Miller KM, et al. : State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther 2019;21:66–72
    1. Duffus SH, Ta'ani ZA, Slaughter JC, et al. : Increased proportion of time in hybrid closed-loop “Auto Mode” is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Diabetes Obes Metab 2020;22:688–693
    1. Kimbell B, Rankin D, Ashcroft NL, et al. : What training, support, and resourcing do health professionals need to support people using a closed-loop system? A qualitative interview study with health professionals involved in the closed loop from onset in type 1 diabetes (CLOuD) trial. Diabetes Technol Ther 2020;22:468–475
    1. Messer LH, Forlenza GP, Sherr JL, et al. : Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care 2018;41:789–796
    1. Messer LH, Berget C, Forlenza GP: A clinical guide to advanced diabetes devices and closed-loop systems using the CARES Paradigm. Diabetes Technol Ther 2019;21:462–469
    1. Schoelwer MJ, Robic JL, Gautier T, et al. : Safety and efficacy of initializing the Control-IQ artificial pancreas system based on total daily insulin in adolescents with type 1 diabetes. Diabetes Technol Ther 2020;22:594–601
    1. O'Malley G, Henderson R, Levy C, et al. : Clinical management of a closed-loop control (CLC) System: results from a 6-month multicenter randomized clinical trial (RCT). J Diabetes Sci Technol 2020;14:A78
    1. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. : Closed-loop control (CLC) in teens and young adults improves glycemic control: results from a 6-month multicenter randomized clinical trial (RCT). Pediatr Diabetes 2019;20:232.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe